The Ferret's stock to watch yesterday.Reprinted below, I don't...

The Ferret's stock to watch yesterday.

Reprinted below, I don't hold CYT

>>>>>>>>>>>

Ferret's Stock to Watch: CYTOPIA LIMITED
07:31, Tuesday, 23 November 2004

BIOTECH RESEARCHER FAST TRACKING ANTI-CANCER DRUG PROGRAM

Sydney - Tuesday - November 23: (RWE Australian Business News)
********************************

OVERVIEW
********

Shareholders of biotech Cytopia heard of some interesting company
developments at yesterday's annual meeting.

The good news is that the company will co-develop its drug with
Cancer Research UK in a bid to fast track its anti-cancer drug program.

Its novel anti-cancer drug, CYT997, had been accepted by
Cancer Research UK into its clinical trial program.

This will give Cytopia direct access to leading British
oncologists and world-class clinical trial facilities.

Cancer Research UK is a non-profit cancer research organisation
specialising in the rapid advancement of promising anti-cancer agents.

It has taken over 100 new drugs into man for the first time.

CYT997 is a novel microtubule-targeting agent specifically
developed by Cytopia research scientists to be orally active.

In animal models of cancer, orally administered CYT997
significantly inhibited tumour growth without adverse effects.

In another report to the Australian Stock Exchange yesterday
Cytopia managing director Dr Kevin Healey said, "We are building a
pipeline of drug candidates across therapeutic areas such as cancer,
immune diseases and cardiovascular disorders, and this year have made
great progress with our cancer drug candidate, CYT997, as well as with
several kinase inhibitors.

"The company has never been in a stronger position, both with
respect to the status of its technology and its cash reserves.

"CYT997 is set to be tested in cancer patients in the first
quarter of calendar 2005 and our JAK3 kinase program has attracted
worldwide attention from pharmaceutical companies," he said.

"We are confident of the timeline for the clinical development
of CYT997 and believe that our JAK3 program is world-competitive and
attractive to pharma companies.

"In the coming year we also expect to add JAK2 to our pipeline
of drug candidates and possibly one or more other kinase inhibitors.

"We are well positioned to become a world leader in
kinase-inhibitor drug development," Dr Healey said.

SHARE PRICE MOVEMENTS
*********************

Shares of Cytopia yesterday rose 6c to 68c. Rolling high for the
year has been 77.88c and low 45.43c.

Cytopia has implemented a broad discovery program targeting
immune disease and cancer.

The company's objective is to develop new, small molecule drugs
that can disrupt aberrant cellular control mechanisms in these diseases,
at the level of cell surface receptors, as well as their intracellular
signalling mechanisms.

Its major focus is on the protein tyrosine kinase family of
enzymes (PTKs) many of which play pivotal roles in cell signalling.
Kinases are now well-validated drug discovery targets, with the launch of
Glivec (also known as Gleevec or imatinib) by Novartis in 2001 to treat
chronic myelogenous leukemia.

Cytopia's strategy is to progressively assess all of the
molecules in our diverse chemical library for activity against a broad
range of kinase targets (a concept known as Parallel Chemical Genetics).

This program generates a matrix of data, leading to a deep
understanding of the chemical structures that determine specificity and
potency against multiple targets.

In this way, Cytopia is building a pipeline of drug candidates
for a broad range of clinical needs.

Cytopia has established a multi-disciplinary, integrated research
team which applies rational drug design technologies to accelerate the
discovery of drug candidates.

This includes a significant emphasis on the use of in silico
technologies to reduce the burden in chemical library production and to
increase the probability of identifying specific and potent inhibitors.


BACKGROUND
**********

Cytopia is a Melbourne-based drug discovery and development
company committed to redefining the way medicines are discovered.

The company is positioned at the cutting-edge of structure-based
rational drug design and discovery.

Cytopia's aim is to discover and develop a new generation of
therapeutic drugs for cancer and immune diseases.

Already, Cytopia has applied its medicinal chemistry capability,
high-throughput screening facility and computational chemistry platform
to develop a broad pipeline of novel pre-clinical drug candidates.

Cytopia is focusing its drug development strategy on major areas
of unmet clinical need.

Major therapeutic targets are: Cancer, (specifically Prostate
Cancer, Lymphoma, Leukemia, and Multiple Myeloma); and Immune Disease,
(including Rheumatoid Arthritis and Atopic diseases, such as Eczema and
Asthma). Cytopia has built up an impressive portfolio of granted patents
and patent applications protecting significant intellectual property real
estate, including both proprietary drug discovery targets and new
Composition Of Matter patents on novel drug-like enzyme inhibitors.

Fully integrated new laboratory facility is located in the heart
of Melbourne, Australia and has links to the Baker Heart Research
Institute, the Alfred hospital and Monash University.

Cytopia will maximise shareholder value by discovering,
developing and commercialising a pipeline of new chemical entities, aimed
at the treatment of certain cancers and immune-related diseases and
disorders.

The company's business strategy is to build a judicious mix of
in-house late stage clinical development projects with early stage
partnering opportunities.

Its overall strategy is to add maximum value to each stream of
our activities where we have the resources to do so.

This program generates a matrix of data, leading to an
understanding of the chemical structures which determine specificity and
potency against multiple targets.

In this way, Cytopia will build a pipeline of drug candidates for
a broad range of clinical needs.

ENDS

Copyright © 2004 RWE Australian Business News. All rights reserved.